Israel's Innovation Authority has announced a NIS 70 million investment in the Israel BioToken Factory Initiative (IBFI), a consortium designed to create a unified technological infrastructure that allows artificial intelligence systems to process and understand complex biological data in ways they currently cannot. The initiative brings together NVIDIA, pharmaceutical giant Teva, Sheba Medical Center, biotech startups, and leading research universities to solve a fundamental problem: biology still does not speak a language that AI can understand.

Why Can't AI Models Understand Biological Data Today?

The challenge facing the life sciences industry is deceptively simple but technically profound. Biological systems are extraordinarily complex, involving molecular interactions, cellular dynamics, immune responses, and patient-specific variations that exist across multiple scales simultaneously. Current AI models struggle to integrate these different types of data into a coherent framework that can make meaningful predictions about disease progression, treatment responses, or drug efficacy. The consortium aims to change this by creating what it calls "Bio Tokens," a standardized representation layer that translates different types of biological information into a format that AI systems can reliably process and learn from.

"Everyone is talking today about AI in biology, but biology still does not speak a language that AI can understand. IBFI was established to build the infrastructure and the language on which the next generation of biological AI will be based," stated Yoav Nissan Cohen, Chairman of the Consortium and CEO of TerraCyte.

Yoav Nissan Cohen, Chairman of the Consortium and CEO of TerraCyte

What Will This Shared Infrastructure Actually Do?

The consortium is developing two core technological components that will work together to enable a new generation of AI-driven medical breakthroughs. The first component, Bio Tokens, provides a standardized representation layer for different types of biological data. The second, called the Factory Model, serves as a platform that enables the development, integration, execution, and accessibility of AI-based biological models. Together, these components will make it possible to connect molecular, cellular, dynamic, and clinical data within a single computational framework, creating a shared infrastructure that serves industry, academia, and the healthcare system.

The partners in this initiative represent a cross-section of Israel's life sciences ecosystem. Industry participants include CytoReason, TerraCyte Analytics, and MeMed, alongside technology and pharmaceutical leaders NVIDIA, Teva, and Sheba Medical Center. Scientific leadership comes from prominent researchers at the Weizmann Institute of Science, the Technion, and Ben-Gurion University of the Negev. This collaboration is intentionally designed as a pre-competitive effort, meaning all partners contribute to and benefit from the shared infrastructure rather than competing over proprietary versions.

How Will This Infrastructure Improve Patient Care?

The consortium's initial applications are expected to focus on several high-impact clinical areas. These include:

• Oncology Treatment Response: Predicting which cancer patients will respond to specific therapies, reducing trial-and-error approaches and improving outcomes.
• Immune System Assessment: Evaluating immune system activity to better understand disease progression and treatment efficacy.
• Drug Hypersensitivity Prediction: Identifying patients at risk for severe adverse reactions before they receive medications.
• Sepsis Clinical Support: Supporting clinical decision-making in sepsis cases, where rapid, accurate diagnosis can be lifesaving.
• Transplant and Autoimmune Monitoring: Assessing transplant rejection risk and monitoring autoimmune disease progression.
• Drug Discovery Acceleration: Speeding up the identification and development of new therapeutic compounds.

By enabling AI systems to understand biological complexity at this level, the infrastructure could fundamentally change how quickly new treatments move from laboratory discovery to clinical use. The ability to predict treatment responses and identify drug candidates more accurately means fewer failed clinical trials and faster paths to patients who need new therapies.

"In recent years, artificial intelligence has transformed the way we develop drugs, research diseases, and understand biological systems. Today, the major challenge is no longer simply developing more advanced models but building the infrastructure that will enable those models to learn from the complexity of human biology," explained Dror Bin, CEO of the Israel Innovation Authority.

Dror Bin, CEO of the Israel Innovation Authority

Why Does This Matter for the Broader AI Healthcare Landscape?

This initiative represents a strategic shift in how countries are approaching AI in healthcare. Rather than individual companies or research groups building proprietary AI systems in isolation, Israel is investing in shared foundational infrastructure that can serve the entire ecosystem. This approach accelerates innovation because startups, hospitals, and researchers can all build on the same standardized platform rather than each starting from scratch. It also reduces redundancy and allows resources to focus on solving novel problems rather than repeatedly solving the same data representation challenges.

The investment aligns with Israel's broader policy of advancing breakthrough technological infrastructures that connect industry, academia, and the healthcare system. By strengthening Israel's competitive advantage in artificial intelligence, biotechnology, and personalized medicine, the Authority seeks to enable the development of technologies that will serve both industry and the healthcare system in the years ahead.

The consortium's work is expected to accelerate the timeline for bringing AI-driven medical innovations to patients. When AI systems can reliably understand and integrate biological data, the path from research discovery to clinical application becomes shorter and more predictable. This could mean faster drug approvals, more personalized treatment plans, and ultimately, better health outcomes for patients worldwide.